BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd., UK submitted on 1 April 1997 an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Exelon 
hard capsules, through the centralised procedure. After agreement by the CPMP on 18-21 November 
1996,  this  medicinal  product  is  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No.  (EC) 
2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. E. Abadie 
Co-Rapporteur:   Dr. P. Sjöberg 
Licensing status: 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 18 April 1997. 
During  the  17-18  June  CPMP  meeting,  a  GMP  inspection  of  the  manufacturing  site  in  Basel, 
Switzerland, was agreed upon. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 25 June 1997. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  members  on 
27 June 1997. 
During  its  meeting  on  22-24  September  1997,  the  CPMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 24 September 1997. 
The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  10  November 
1997. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  joint  response  assessment  report  on  the 
company’s responses to the list of questions to all CPMP members on 9 December 1997.  
During its meeting on 16-17 December 1997, the CPMP agreed on a list of outstanding issues to 
be addressed by the company in writing and in an oral explanation. 
The company submitted the responses on the outstanding issues on 7 January 1998. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  a  further  joint  response  assessment  report, 
taking into account the company’s responses on the outstanding issues, to all CPMP members 
on 26 January 1998. 
A  hearing  was  held  at  the  CPMP  meeting  on  27  January  1998,  to  address  the  remaining 
outstanding issues.  
The CPMP, during their meeting on 27-28 January 1998, considered the responses provided by 
the  company  and  discussed  the  recommendations  presented  by  the  Rapporteur.  Amendments 
were discussed to the Summary of Product Characteristics and Package Leaflet texts. 
During the meeting on 27-28 January 1998 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  (majority)  for 
granting a Marketing Authorisation for Exelon hard capsules on 28 January 1998. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission which adopted the corresponding Decisions on 12 May 1998. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
